RESUMO
Purpose: This study aimed to analyze the effect of body mass factors (BMFs) on setup errors in gynecologic tumors, and whether the planned tumor volumes (PTVs) are adequate for obese patients. Methods: This was a retrospective study of 46 consecutive female patients with gynecologic tumors who were treated with volumetric modulated arc therapy. Setup accuracy was verified using daily cone beam computed tomography. Accuracy was determined for each fraction by testing 2 different PTVs (cutoff I = ≤0.7 cm; cutoff II = ≤1.0 cm). A pooled analysis was conducted to test the association between accuracy levels (within vs beyond PTV) and the mean and variance of body mass index (BMI), umbilical (UC), and hip circumference (HC). A receiver operating characteristics curve analysis was carried out to test the sensitivity of BMI, UC, and HC in predicting inaccurate setup. Results: A significant association between BMFs and level of accuracy was observed in the lateral and vertical directions, but not in the longitudinal direction. In the lateral direction, inaccurate setups were associated with a greater BMI (mean difference: â¼3.50 kg/m2; P = .001), UC (â¼10 cm), and HC (â¼8 cm) compared with accurate setups (P < .001). With respect to the vertical direction, inaccurate setups (>0.7 cm margin [cutoff I]) were associated with a greater BMI (mean difference = 7.4 kg/m2; P = .001), UC (5.3 cm; P < .001), and HC (16.0 cm; P < .001) with reference to accurate setups. The receiver operating characteristics curve analysis showed that a BMI >31.4 kg/m2 was predictive for inaccurate setup in the vertical direction with 90.0% sensitivity with respect to cutoff I. Furthermore, a BMI >30.3 kg/m2 was predictive for inaccurate setup in the lateral direction with 92.5% sensitivity with respect to cutoff II. Conclusions: The accuracy of radiation therapy setups for gynecologic tumors is highly sensitive to patients' BMI, notably in the lateral and vertical directions. We suggest that daily cone beam computed tomography should be applied on patients with a BMI >30.3 kg/m2, using customized protocols that are lower in dose and comparable in image quality.
RESUMO
Adrenocortical cancer is a rare neoplasm with varied clinical presentation and overall poor outcome. This should be managed with timely intervention at highly specialized centers. Our aim is to report this rare case presentation of large non-functional adrenocortical cancer, complicated by spontaneous rupture while awaiting workup leading to life-threatening hemorrhage. Despite successful emergency radical surgical management and achieving negative margins, the patient developed early recurrence as intra-abdominal metastasis within two months. This can likely be attributed to the aggressive nature of the tumor as indicated by the high Ki-67 index or spillage of the tumor cells following spontaneous rupture. We recommend managing these non-functioning adrenocortical cancers as early as possible at highly specialized centers with reference to published standard guidelines.
RESUMO
This published article omitted a reference to the paper.
RESUMO
BACKGROUND: Adhesive small bowel obstruction (ASBO) is a common post-operative cause of hospitalisation. Water-soluble contrast media (WSCM) has become a popular non-surgical approach to treatment. However, previous reviews have concluded with conflicting results. This meta-analysis of randomised controlled trials (RCTs) re-evaluated the therapeutic value of WSCM in the management of ASBO. METHODS: A comprehensive search of PubMed, Embase, and Cochrane databases was undertaken to identify RCTs from January 2000 to November 2018. The primary outcomes of length of stay and secondary outcomes of time to resolution, need for surgery, and mortality were extracted from the included studies. Quantitative pooling of the data was based on the random effects model. RESULTS: Eight hundred and seventy-nine patients from the nine studies were included in the analysis. The administration of oral WSCM reduced the length of hospital stay (weighted mean difference - 0.15 days, P < 0.0001). However, WSCM does not reduce the need for surgery (relative risk 0.84, P < 0.009) and makes no difference to mortality rate (RR 0.99, P < 1.000). The definition of time to resolution of ASBO differed between the studies, ranging from time to passing flatus, to cessation of abdominal pain, and time to initiating oral intake. The significant differences in definition precluded meaningful quantitative pooling of this outcome. CONCLUSIONS: This meta-analysis evaluating the therapeutic value of WSCM has shown that it does not reduce the need for operative management in ASBO or impact mortality rates. It shortens hospital stay by 0.15 days (3.6 h) which is not clinically significant.
